Home
Resources
Publications
Inhibitors of interleukin-1 Receptor-Associated Kinase 4 (IRAK4): A Patent Review (2012-2015)

Inhibitors of interleukin-1 Receptor-Associated Kinase 4 (IRAK4): A Patent Review (2012-2015)

W Michael Seganish

Expert Opin Ther Pat. 2016 Aug;26(8):917-32.

PMID: 27310003

Abstract:

Introduction:
IRAK4 is located proximal to TLR/IL-1 receptors, and in preclinical studies, inhibits downstream signaling from these receptors. The development of novel small molecule inhibitors of this kinase has the potential to lead to new therapeutics to treat diseases such as rheumatoid arthritis, lupus, and lymphomas.
Areas covered:
The aim of this review is to summarize the recent patent literature (2012-2015) surrounding small molecule inhibitors of IRAK4. Specific examples of the chemical matter from each patent will be discussed, including any data that are presented for the examples highlighted.
Expert opinion:
There are currently many examples of highly potent and kinase selective IRAK4 inhibitors and some have been tested in various in vivo disease models, demonstrating robust pre-clinical efficacy. Several compounds appear to have the 'drug-like' properties to advance to the clinic, with Pfizer having already initiated several phase I studies.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1817626542	PF06650833		1817626-54-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: